AIM: To investigate the pathophysiology of irritable bowel syndrome (IBS) by comparing the global mucosal metabolic profiles of IBS patients with those of healthy controls. METHODS: Fifteen IBS patients fulfilling the Rome II criteria, and nine healthy volunteers were included in the study. A combined lipidomics (UPLC/MS) and metabolomics (GC x GC-TOF) approach was used to achieve global metabolic profiles of mucosal biopsies from the ascending colon. RESULTS: Overall, lipid levels were elevated in patients with IBS. The most significant upregulation was seen for pro-inflammatory lysophosphatidylcholines. Other lipid groups that were significantly upregulated in IBS patients were lipotoxic ceramides, glycosphingolipids, and di- and triacylglycerols. Among the metabolites, the cyclic ester 2(3H)-furanone was almost 14-fold upregulated in IBS patients compared to healthy subjects (P = 0.03). CONCLUSION: IBS mucosa is characterised by a distinct pro-inflammatory and lipotoxic metabolic profile. Especially, there was an increase in several lipid species such as lysophospholipids and ceramides.
AIM: To investigate the pathophysiology of irritable bowel syndrome (IBS) by comparing the global mucosal metabolic profiles of IBSpatients with those of healthy controls. METHODS: Fifteen IBSpatients fulfilling the Rome II criteria, and nine healthy volunteers were included in the study. A combined lipidomics (UPLC/MS) and metabolomics (GC x GC-TOF) approach was used to achieve global metabolic profiles of mucosal biopsies from the ascending colon. RESULTS: Overall, lipid levels were elevated in patients with IBS. The most significant upregulation was seen for pro-inflammatory lysophosphatidylcholines. Other lipid groups that were significantly upregulated in IBSpatients were lipotoxic ceramides, glycosphingolipids, and di- and triacylglycerols. Among the metabolites, the cyclic ester 2(3H)-furanone was almost 14-fold upregulated in IBSpatients compared to healthy subjects (P = 0.03). CONCLUSION:IBS mucosa is characterised by a distinct pro-inflammatory and lipotoxic metabolic profile. Especially, there was an increase in several lipid species such as lysophospholipids and ceramides.
Authors: Francois-Pierre J Martin; Elena F Verdu; Yulan Wang; Marc-Emmanuel Dumas; Ivan K S Yap; Olivier Cloarec; Gabriela E Bergonzelli; Irene Corthesy-Theulaz; Sunil Kochhar; Elaine Holmes; John C Lindon; Stephen M Collins; Jeremy K Nicholson Journal: J Proteome Res Date: 2006-09 Impact factor: 4.466
Authors: George F Longstreth; W Grant Thompson; William D Chey; Lesley A Houghton; Fermin Mearin; Robin C Spiller Journal: Gastroenterology Date: 2006-04 Impact factor: 22.682
Authors: Shen-Hao Wang; Lei Dong; Jin-Yan Luo; Jun Gong; Lu Li; Xiao-Lan Lu; Shui-Ping Han Journal: World J Gastroenterol Date: 2007-12-07 Impact factor: 5.742
Authors: Bin Feng; Jun-Ho La; Erica S Schwartz; Takahiro Tanaka; Timothy P McMurray; G F Gebhart Journal: Am J Physiol Gastrointest Liver Physiol Date: 2012-01-19 Impact factor: 4.052
Authors: Iftikhar Ahmed; Rosemary Greenwood; Ben de Lacy Costello; Norman M Ratcliffe; Chris S Probert Journal: PLoS One Date: 2013-03-13 Impact factor: 3.240
Authors: Natalia Zeber-Lubecka; Maria Kulecka; Filip Ambrozkiewicz; Agnieszka Paziewska; Krzysztof Goryca; Jakub Karczmarski; Tymon Rubel; Wojciech Wojtowicz; Piotr Mlynarz; Lukasz Marczak; Roman Tomecki; Michal Mikula; Jerzy Ostrowski Journal: Gut Microbes Date: 2016-07-26